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YARS2 variants have previously been described in patients withmyopathy, lactic acidosis and sideroblastic anemia 2 (MLASA2).YARS2 encodes the mitochondrial tyrosyl-tRNA synthetase,
which is responsible for conjugating tyrosine to its cognate mt-tRNA for
mitochondrial protein synthesis. Here we describe 14 individuals from
11 families presenting with sideroblastic anemia and YARS2 variants that
we identified using a sideroblastic anemia gene panel or exome sequenc-
ing. The phenotype of these patients ranged from MLASA to isolated
congenital sideroblastic anemia. As in previous cases, inter- and intra-
familial phenotypic variability was observed, however, this report
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ABSTRACT
Introduction
Sideroblastic anemia is defined by the presence of bone
marrow ringed sideroblasts, which are erythroblasts con-
taining pathological intramitochondrial iron deposits.1
Congenital sideroblastic anemias (CSAs) are caused by a
growing list of genetic variants that affect mitochondrial
pathways, including heme synthesis, iron-sulfur cluster
biogenesis, mitochondrial protein synthesis, and oxidative
phosphorylation.2,3 Variants in YARS2 have been associat-
ed with myopathy, lactic acidosis, and sideroblastic ane-
mia 2 (MLASA2; OMIM #613561),4-8 and recently cases of
YARS2-related myopathy in the absence of sideroblastic
anemia have been reported.9 YARS2 encodes the mito-
chondrial tyrosyl-tRNA synthetase, YARS2, which is
responsible for the ATP-dependent conjugation of tyro-
sine to its cognate tRNA, required to support mitochondr-
ial protein synthesis.10 YARS2 catalyses this reaction in a
two-step process. In the first step, tyrosine and ATP bind
to the catalytic domain to form the tyrosyl-adenylate
intermediate. In the second step, cognate tRNATyr binds
the synthetase and the tyrosyl moiety is transferred to the
tRNA CCA-end. The resulting tyrosyl-tRNATyr will be
delivered to the ribosome. 
The most commonly reported YARS2 variant,
p.(Phe52Leu), prevalent in patients of Lebanese Christian
descent, has been shown to reduce YARS2 amino-acyla-
tion catalytic efficiency by approximately 9-fold, and
leads to a reduction in mitochondrial protein synthesis in
patients with MLASA2.4 Here we report YARS2 variants,
some of which were associated with milder effects on
amino-acylation, in patients with isolated CSA, or CSA
with mild myopathy and lactic acidosis. In addition, we
describe two pairs of genotypically identical siblings with
divergent, affected and unaffected, clinical phenotypes.
Importantly, some patients carry a common YARS2 c.572
G>T, p.(Gly191Val), that we and others have previously
shown has a mild effect on amino-acylation activity,5,11
and suggest that these milder alleles may be the basis of
the reduced penetrance and expressivity.
Methods
Clinical data
The patients and their immediate family members were
referred to MMH, MDF, NS or LA for clinical consultation. Written
informed consent was obtained from participants in the study, as
approved by the Institutional Review Boards of Boston Children’s
Hospital, USA, the Radboud University Medical Center, the
Netherlands, and the Hospital Germans Trias i Pujol, Badalona,
Spain. In each case, CSA was ascertained by complete blood
counts (CBCs), and peripheral blood or bone marrow morpholo-
gy. Detailed clinical histories are provided in the Online
Supplementary Appendix.
Variant detection
Targeted sequencing of nuclear encoded CSA genes,12 and the
mitochondrial genome as well as mitochondrial DNA deletion
analysis was performed on the probands of families 1-3 and 5-9.
Genomic DNA was isolated from peripheral blood or skin fibrob-
lasts, using the Puregene DNA Purification Kit (Qiagen, Valencia,
CA, USA). DNA templates for sequencing were amplified from
genomic DNA by PCR, enzymatically cleaned, bidirectionally
sequenced using fluorescent dye termination sequencing chem-
istry, and analyzed with the Sequencher 5.3 DNA sequence
assembly software (Gene Codes, Ann Arbor, MI, USA), as previ-
ously described.12 
Exome sequencing for Patient 4 was performed on genomic
DNA isolated from whole blood. The experimental workflow
was performed at BGI Europe (Bejing Genome Institute Europe,
Copenhagen, Denmark) using an Illumina Hiseq (Illumina, CA,
USA) platform. Variants in genes previously associated with
Mendelian diseases (OMIM), including CSAs, were analyzed
bioinformatically.
Patient 10 DNA was analyzed using a targeted gene panel for
congenital and acquired sideroblastic anemias, including ABCB7,
ALAS2, GLRX5, PUS1, SF3B1, SLC19A2, SLC25A38, STEAP3,
TRNT1 and YARS2. The library was constructed using the Custom
HaloPlex™ Target Enrichment System (Agilent, Santa Clara, CA,
USA) and sequenced on a MiSeq platform (Illumina, San Diego,
CA, USA). Data were analyzed with SureCall software (Agilent,
Santa Clara, CA, USA).
Patient 11 DNA was analyzed using a targeted gene panel for
sideroblastic anemia (ABCB7, ALAS2, GLRX5, HSCB, HSPA9,
PUS1, SLC25A38, STEAP3, YARS2) and ion semiconductor
sequencing as developed by Ion Torrent systems.13  
In silico predictions of variant pathogenicity were performed
using the Alamut Visual suite of genetic analysis software
(Interactive Biosoftware, Rouen, France), and linking externally to
the PolyPhen2 and SIFT analytical tools.14,15 Minor allele frequen-
cies are reported as in gnomAD (gnomad.broadinstitute.org) current
as of September 2017.16 
Amino-acylation assays
Recombinant wild-type and the p.(Leu61Val), p.(Met195Ile),
p.(Ser203Ile), p.(Tyr236Cys) and p.(Gly244Ala) YARS2 variants
were expressed in E. coli, purified to homogeneity and assayed for
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includes the first cases with isolated sideroblastic anemia and patients with biallelic YARS2 variants that
have no clinically ascertainable phenotype. We identified ten novel YARS2 variants and three previously
reported variants. In vitro amino-acylation assays of five novel missense variants showed that three had
less effect on the catalytic activity of YARS2 than the most commonly reported variant, p.(Phe52Leu),
associated with MLASA2, which may explain the milder phenotypes in patients with these variants.
However, the other two missense variants had a more severe effect on YARS2 catalytic efficiency.
Several patients carried the common YARS2 c.572 G>T, p.(Gly191Val) variant (minor allele frequency =
0.1259) in transwith a rare deleterious YARS2 variant. We have previously shown that the p.(Gly191Val)
variant reduces YARS2 catalytic activity. Consequently, we suggest that biallelic YARS2 variants, includ-
ing severe loss-of-function alleles in trans of the common p.(Gly191Val) variant, should be considered as
a cause of isolated congenital sideroblastic anemia, as well as the MLASA syndromic phenotype.
tyrosylation activity as previously described.10 Apparent kinetic
parameters were determined from Lineweaver-Burk plots in the
presence of 4.8 to 6.5 nM YARS2 and 0.28 to 1.12 mM native E. coli
tRNATyr (Sigma, St. Louis, MO, USA). Experimental errors on kcat
and Km varied at most by 20%. Numerical values are averages of
at least two independent experiments.
Results
Phenotypic spectrum
Eleven probands with CSA were identified with poten-
tially pathogenic YARS2 variants by targeted gene
sequencing panels or exome sequencing (Table 1A and
1B). The majority of these families were derived from a
group of more than 200 probands with CSA referred to
SSB, MDF and MMH, in which approximately 4% of
cases were attributed to YARS2 variants. YARS2 variants
have previously been identified in patients with myopa-
thy, lactic acidosis and sideroblastic anemia 2 (MLASA2);4
however, some patients in this study did not have overt
clinical features of MLASA2 other than CSA, and several
individuals with biallelic variants had no phenotype what-
soever. In two families, the proband had moderate sider-
oblastic anemia (P8a and P9a), while a sibling with the
same YARS2 genotype was not anemic and was otherwise
L.G. Riley et al.
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Table 1A. Clinical data. 
Participant ID P1 P2a P2b P3 P4 P5 P6
YARS2 variant 1 c.156C>G c.156C>G c.156C>G c.156C>G c.181C>G c.585G>A c.572G>T
(NM_001040436.2) p.(Phe52Leu) p.(Phe52Leu) p.(Phe52Leu) p.(Phe52Leu) p.(Leu61Val) p.(Met195Ile) p.(Gly191Val)
YARS2 variant 2 c.156C>G c.156C>G c.156C>G c.156C>G c.181C>G c.1165_1166insG c.590_625del
p.(Phe52Leu) p.(Phe52Leu) p.(Phe52Leu) p.(Phe52Leu) p.(Leu61Val) p.(Leu389Cysfs*6) p.(Thr197_Leu208del)
Year of birth 1988 2007 2009 2007 1986 2001 1998
Gender Female Male Female Male Male Female Female
Ethnicity Lebanese/ Lebanese Lebanese Lebanese Caucasian/ Caucasian/ African
American Dutch American American
Consanguinity No Yes Yes No Yes No No
Age at presentation 14 years 6 years 4 years 9 years 19 years 2 years 20 months
Sideroblastic Severe, Severe, Mild Moderate Severe, Severe, Severe, 
anemia transfusion transfusion transfusion transfusion transfusion
dependent dependent dependent dependent dependent
from 27 years from 6 years intermittently intermittently from 20 months
from 20 years from 2 years
Hemoglobin, g/dL 9.9 10.5 11.5 9.5 6.6 3 2
MCV, fL 84.5 111 102 92.4 81 82.6 101
Abs Retic, M/mL 0.101 0.035 0.13 0.132 ND 0.0175 0.016
Retic, % 3.1 1 2.9 2 1.1 1.7 2.3
WBC x109/L 2.41 4.35 6.6 5.2 5.4 3.63 6.2
ANC x109/L 780 2960 3480 2012 ND 617 861-2070
Platelets x109/L 294 195 305 216 374 163 324
RS, % of BM erythroblasts 10 ND ND 30 56 ND >15
Transferrin saturation, % 60 (2002) 97 (2016) 80 (2016) 45 90 (2014) 53 91 (2000)
Ferritin, ng/mL 34.4 (2002) 825 (2016) 296 (2016) 61 683 (2014) 93 256 (2000)
Chelation No Yes Yes No Yes Yes Yes 
(year started) (2016) (2017) (2012) (2011) (2004)
Lactic acidosis Severe ND ND Severe Exercise Premortem Mild
9.1 mmol/L 9.5 mmol/L induced only only
Myopathy Severe None None Mild None Mild None
Other clinical Sinus Atrial None Diarrhea, Successful Mild Thrombocytopenia, 
features tachycardia, septal hepatosplenomegaly stem cell cardiomyopathy intermittent
pericardial effusion, defect transplant neutropenia
neutropenia at 28 years
thrombocytopenia, 
primary ovarian failure
Vital status Deceased at 28 y Alive Alive Alive Alive Deceased at 12 y Alive
MCV: mean corpuscular volume; retic: reticulocytes; WBC: white blood cell count; ANC: absolute neutrophil count; RS: ringed sideroblasts; BM: bone marrow; ND: not deter-
mined; y: years.
asymptomatic (P8b and P9b) (Table 1B). In a third family
(P2a and P2b) (Table 1A), the proband was identified with
a severe, new onset anemia at six years of age, and, sub-
sequent to her brother’s diagnosis, the younger sibling
was found to be anemic. Four of the probands presented
within the first two years of life (P5, P6, P7, P9a), and 4
presented in adolescence (P1, P4, P8a, P11). Two patients
have died (P1, P5), both from multi-organ failure, one of
these following two unsuccessful hematopoietic stem cell
transplantations (HSCTs). One patient (P4) has undergone
successful HSCT.
The 11 probands all had moderate to severe normocytic
to macrocytic anemia. In nine probands, the presence of
ringed sideroblasts, ranging from 10% to over 50% of
bone marrow erythroblasts, was documented on bone
marrow aspiration; marrows were not examined in 3
other patients and 2 clinically unaffected siblings (Table
1A and B). Eight patients required transfusion; however,
one patient spontaneously became transfusion independ-
ent at 16 months of age (P7), and 3 patients had periods of
hematologic remission (P4, P5, P9a), transiently becoming
RBC transfusion independent. In addition to anemia, 3
probands had variable neutropenia and/or thrombocy-
topenia (P1, P6, P8a). Four patients were treated with pyri-
doxine with no improvement in their anemia (P4, P5, P6,
P11).
Two patients had severe lactic acidosis (P1, P3), but the
remaining cases in which it was studied had mild or no
lactic acidosis (Table 1A and B). Two patients had elevated
blood lactate upon light exercise (P4, P8a); those with mild
lactic acidosis also tended to have mild myopathy,
although one patient with no reported lactic acidosis had
YARS2 congenital sideroblastic anemia
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Table 1B. Clinical data.
Participant ID P7 P8a P8b P9a P9b P10 P11 
YARS2 variant 1 c.[572G>T;731G>C] c.572G>T c.572G>T c.98C>A c.98C>A c.608G>T c.933C>G
(NM_001040436.2) p.(Gly191Val); (Gly244Ala)] p.(Gly191Val) p.(Gly191Val) p.(Ser33*) p.(Ser33*) p.(Ser203Ile) p.(Asp311Glu)
YARS2 variant 2 c.933C>G c.1360_1361insG c.1360_1361insG c.707A>G c.707A>G c.1104-1G>A c.933C>G
p.(Asp311Glu) p.(Ile454Serfs*10) p.(Ile454Serfs*10) p.(Tyr236Cys) p.(Tyr236Cys) p.? p.(Asp311Glu)
Year of birth 1999 1963 1965 2010 2010 1992 2003
Gender Female Female Female Male Male Female Male
Ethnicity Caucasian/ Caucasian/ Caucasian/ Caucasian/ Caucasian/ Caucasian/ Caucasian /
American American American American American Spanish Dutch 
Consanguinity No No No No No Unknown No
Age at presentation 3 months 18 years 49 years 3 months 3 months 23 years 13 years
(Asymptomatic) (Asymptomatic)
Sideroblastic Severe, transfusion Moderate None Severe, None Moderate Severe
anemia dependent until transfused transfusion
16 months intermittently from dependent from
3 months 13 years 
Hemoglobin, g/dL 5.8 9.9 13.9 2.4 12.8 9.6 6.6
MCV, fL 94.6 111.9 82 113.8 94.1 86 95
Abs Retic, M/mL 0.037 0.059 0.106 0.015 0.053 0.088 0.018
Retic, % 1.8 2.3 2.1 2.4 1.3 2.38 0.8
WBC x109/L 8.01 6 6.8 10.1 9.8 7.65 4.9
ANC x109/L 1201 3600 4340 1919 3180 4280 1700
Platelets x109/L 337 149 182 537 414 243 257
RS, % of BM erythroblasts 47 40 ND >50 ND 32 81 
Transferrin saturation, % ND 66.7 (2015) Unknown 45 (2016) 51 (2015) 79.4 (2015) 62 (2016)
Ferritin, ng/mL ND 387 (2015) Unknown 225 (2016) 42 (2015) 295 (2015) 180 (2016) 
Chelation No No No No No No Yes (2017)
(Year started)
Lactic acidosis None Exercise induced only None None ND None Mild
Myopathy Moderate Mild None None None None Mild
Other clinical Intermittent Dependent None Facial Facial Asthenia None
features diarrhea and edema, leukopenia, dysmorphism dysmorphism
abdominal pain thrombocytopenia, 
atypical pulmonary 
carcinoid tumor (age 53)
Vital status Alive Alive Alive Alive Alive Alive Alive
MCV: mean corpuscular volume; retic: reticulocytes; WBC: white blood cell count; ANC: absolute neutrophil count; RS: ringed sideroblasts; BM: bone marrow; ND: not deter-
mined.
moderate myopathy (P7). Patient 1 (P1) with severe lactic
acidosis and myopathy had combined respiratory chain
deficiency in skeletal muscle, and the muscle biopsy
showed histopathological features typical of a mitochon-
drial myopathy, including ragged red fibers on trichrome
stain and “parking lot” inclusions and whorled arrays of
mitochondrial cristae by transmission electron
microscopy (data not shown). In one family, the proband
(P9a) and his clinically unaffected, but genotypically iden-
tical sibling (P9b),  had distinctive “triangular” faces, unlike
their parents or genotypically normal sibling, which has
not previously been reported in association with YARS2
variants, but has been described in mitochondrial myopa-
thy with lactic acidosis and sideroblastic anemia 1
(MLASA1; OMIM #600462) due to pseudouridine syn-
thase 1 (PUS1) variants.17 
YARS2 variants in patients with congenital 
sideroblastic anemia
We identified three previously described YARS2 variants
and ten novel variants in patients with CSA: the Lebanese
Christian founder variant, p.(Phe52Leu),4 was in the
homozygous state in 4 patients; the p.(Asp311Glu) variant8
homozygous in one patient; and a novel variant,
p.(Leu61Val) homozygous in one patient. The remaining
six families had compound heterozygous variants including
four novel missense variants: p.(Met195Ile), p.(Ser203Ile),
p.(Tyr236Cys), p.(Gly244Ala); a novel nonsense variant
p.(Ser33*); three novel indels, p.(Thr197_Leu208del),
p.(Leu389Cysfs*6), p.(Ile454Serfs*10); one novel splicing
variant, c.1104-1G>A; and two previously reported mis-
sense variants, p.(Gly191Val) and p.(Asp311Glu).5,8 No
patient had two indel or splicing variants.
L.G. Riley et al.
2012 haematologica | 2018; 103(12)
Table 2. In silico predictions of pathogenicity for YARS2 missense variants.
YARS2 SIFT SIFT PolyPhen2 prediction PolyPhen2 gnomAD
variant prediction score score frequency (%)
p.(Leu61Val) Deleterious 0.03 Benign 0.001 0.0016*
p.(Met195Ile) Tolerated 0.17 Possibly damaging 0.827 0
p.(Ser203Ile) Deleterious 0.02 Probably damaging 0.989 0
p.(Tyr236Cys) Tolerated 0.09 Probably damaging 1.000 0.0008*
p.(Gly244Ala) Deleterious 0.00 Probably damaging 0.995 0.0047*
*No homozygotes reported.
Figure 1. Representation of mutated YARS2 proteins. (A) Schematic view of YARS2 domains: MTS: mitochondrial targeting sequence; ACB: anticodon binding
domain; S4-Like: S4 ribosomal protein-like domain. Amongst all the variants identified, only those tested in this study are shown in cyan. Note that the recombinant
YARS2 used in the amino-acylation assays is deprived of the MTS. (B) Model of YARS2 p.(Thr197-Leu208del), built with I-TASSER.28 The structural domains from (A)
are shown with the same color code. The locations of the variants, which have the weakest effects on amino-acylation [p.(Leu61Val), p.(Met195Ile), p.(Tyr236Cys)]
are shown in cyan. (C) Crystal structure of YARS2 catalytic domain19 with the tyrosyl-adenylate analog (TyrAMS, magenta) bound to the active site. The locations of
variants p.(Ser203Ile) and p.(Gly244Ala), characterized by the strongest effects on amino-acylation, are indicated in cyan.
A
B C
The five novel missense variants all lie in the catalytic
domain of YARS2 (Figure 1A) and are rare in the gnomAD
database (gnomad.broadinstitute.org) (Table 2). In silico pre-
dictions of pathogenicity for p.(Leu61Val), p.(Met195Ile)
and p.(Tyr236Cys) vary between the SIFT and PolyPhen2
prediction programs while p.(Ser203Ile) and p.(Gly244Ala)
are predicted to be damaging to the YARS2 protein by
both algorithms (Table 2 and  Figure 1B). Conservation
among species for each missense variant is shown in
Online Supplementary Figure S1.
The nonsense variant, the splicing variant and three
novel indels are likely to be deleterious. The splicing vari-
ant c.1104-1G>A alters a canonical position in the 3ʹ splice
acceptor site of intron 3 and it is predicted to result in skip-
ping of exon 4. The YARS2 c.98C>A, p.(Ser33*) nonsense
variant and the c.1165_1166insG, p.(Leu389Cysfs*6)
frameshift variant both lie greater than 55 nucleotides
upstream of the last exon-exon junction and are most like-
ly targeted for nonsense mediated decay.18 The
p.(Thr197_Leu208) in frame deletion results in loss of 12
residues in α-helical regions of the catalytic domain, and
more precisely of cluster 1, which is important for tRNA
acceptor end recognition19 (Figure 1B). The
c.1360_1361insG, p.(Ile454Serfs*10) variant lies in the last
exon of YARS2 and is not predicted to be targeted for non-
sense mediated decay.18 This variant would cause a
frameshift at position 454 in the S4-like domain, which is
found in all prokaryotic and organellar tyrosyl-tRNA syn-
thetases, and is thought to stabilize the interaction
between the tRNA and YARS2.19,20 
Amino-acylation activity of YARS2 missense variants
Amino-acylation assays are commonly used to evaluate
the effect of variants on aminoacyl-tRNA synthetase
activity, with reduced activity being a strong predictor of
pathogenicity.21 Consequently, the effect of the five mis-
sense variants, p.(Leu61Val), p.(Met195Ile), p.(Ser203Ile),
p.(Tyr236Cys) and p.(Gly244Ala) on amino-acylation
activity was measured by the incorporation of [14C]-tyro-
sine into an E. coli tRNATyr substrate and compared to wild-
type YARS2 activity. In vitro studies of the YARS2 variants
revealed that amino-acylation efficiency was mildly
reduced for p.(Leu61Val) and, p.(Met195Ile),  while
p.(Tyr236Cys) was not affected as compared to the wild-
type enzyme (Table 3). YARS2 p.(Ser203Ile) and
p.(Gly244Ala) demonstrated a 17-fold loss in catalytic effi-
ciency. The reduced activity of YARS2 p.(Ser203Ile) is a
consequence of an increased Km, indicating that its affinity
for tRNATyr was reduced.  On the other hand, the YARS2
p.(Gly244Ala) is characterized by a 13-fold lower kcat sug-
gesting that the variant hinders efficient transfer of the
tyrosyl moiety from the active site to the tRNA.  
Discussion
Here we expand the clinical spectrum associated with
YARS2 variants and describe patients with milder pheno-
types who do not display all the features of MLASA2.
Rather, most of the patients we describe presented princi-
pally with a normo- or macro-cytic CSA; they are mostly
non-syndromic and unlike the most common forms of
non-syndromic sideroblastic anemia (e.g. ALAS2 or
SLC25A38 deficiency), the anemia is not microcytic.
Nevertheless, in addition to ringed sideroblasts, some of
these patients had vacuolization of marrow precursors
and/or other cytopenias that are often seen in the syn-
dromic sideroblastic anemias (e.g. Pearson syndrome),
which may be a diagnostic clue. 
Patients 1 and 3 had all the typical features of MLASA2,
whereas Patients 2a, and 2b, who share homozygosity for
the YARS2 Lebanese founder allele, p.(Phe52Leu), had
only anemia. Patient 1 also had other features not typically
associated with MLASA2, including neutropenia, throm-
bocytopenia, pericardial effusion, and premature ovarian
failure. Neutropenia and pericardial effusion have each
been reported in one other patient homozygous for the
p.(Phe52Leu) variant.5,22 Two other patients in the current
series with other genotypes also had mild or intermittent
neutropenia. Premature ovarian failure is associated with
variants in several mitochondrial aminoacyl-tRNA syn-
thetase-encoding genes including HARS2, LARS2 and
AARS2,23-25 and thus may be a feature common to mito-
chondrial protein synthesis defects. There are now 10
reported individuals homozygous for the YARS2
p.(Phe52Leu) variant5,22 and all have been symptomatic,
supporting complete penetrance of this allele. However,
the great range of phenotypic severity strongly suggests
the presence of other genetic and environmental influ-
ences that can modify the effects of YARS2 deficiency. 
Patient 4 presented in late adolescence with sideroblas-
tic anemia without myopathy and has a homozygous
p.(Leu61Val) variant that diminished the amino-acylation
catalytic efficiency 4-fold. Leu61 is located in a region of
the catalytic domain specific to mitochondrial YARSs that
was proposed to contact the tRNATyr acceptor helix (Figure
1B).19 In this case, HSCT appeared to be an effective treat-
ment, restoring the patient’s hemoglobin levels to normal.
Patient 5 presented in infancy with CSA and was trans-
fusion dependent other than a remission occurring
between three and six years of age; she had no myopathy
until her post-HSCT terminal illness. This patient had a
YARS2 c.1165_1166insG variant predicted to result in a
null allele, and a novel p.(Met195Ile) variant which lies
within cluster 1, in a region involved in recognition of the
tyrosine accepting arm of tRNATyr (Figure 1B).19 Some
YARS proteins (e.g. yeast) have an isoleucine (Ile) at this
position, suggesting that it might be a milder allele.
Indeed, in vitro this mutant had little effect on YARS2 cat-
alytic efficiency. 
Patient 10 is a compound heterozygote for a splicing
mutation (c.1104-1G>A) predicted to cause skipping of
exon 4, and a missense variant p.(Ser203Ile), also located
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Table 3. Kinetic parameters for tyrosylation of E. coli tRNATyr by YARS2
wild-type and novel missense variant recombinant proteins.
YARS2 Km kcat kcat /Km Loss of 
variant (mM) (min-1) (efficiency) efficiency*
(fold change)
WT 0.75 20.0 26.7 1
p.(Leu61Val) 1.45 9.1 6.3 4.2
p.(Met195Ile) 1.90 25.5 13.4 2.0
p.(Ser203Ile) 18.60 28.6 1.5 17.3
p.(Tyr236Cys) 0.70 16.5 23.6 0.9
p.(Gly244Ala) 1.00 1.5 1.5 17.8
*Loss of efficiency is calculated relative to wild-type (WT) YARS2.
in cluster 1. YARS2 (p.Ser203Ile) led to a reduced affinity
for tRNATyr, resulting in a 17-fold loss in catalytic efficien-
cy (Figure 1C). Patient 10 has no lactic acidosis or myopa-
thy, and presented with isolated normocytic anemia and
asthenia, and has not required transfusion. 
Patient 7 presented with anemia in infancy requiring
two transfusions within the first 16 months of life and
then became transfusion independent. She has moderate
myopathy and no lactic acidosis and a compound het-
erozygous genotype: a missense variant, p.(Gly244Ala),
occurring in cis with p.(Gly191Val) and in trans with the
p.(Asp311Glu) variant. Gly244 is a critical residue for tyro-
syl-adenylate binding.19  YARS2 p.(Gly244Ala) only affect-
ed the kcat indicating that, as predicted, this variant hinders
binding of the tyrosyl-adenylate in the active site (Figure
1C). YARS2 Asp311 is involved in the recognition of anti-
codon residue G34 of tRNATyr.19  The p.(Asp311Glu) vari-
ant is respiratory deficient in a yeast model, and patients
homozygous for this allele also have transfusion-depen-
dent sideroblastic anemia in the first year of life; however,
in contrast to patient 7, they have lactic acidosis but no
myopathy.8 Further phenotypic variability for the
p.(Asp311Glu) variant was observed in Patient 11 who
was homozygous for p.(Asp311Glu), with transfusion-
dependent MLASA2. 
In two families in this study (Families 6 and 8), affected
patients have the common p.(Gly191Val) allele (MAF =
0.1259) in trans of a predicted null allele. Importantly, all
of the unaffected carriers of predicted null alleles in these
and other families, where probands had the ancestral
p.Gly191 variant in trans, were asymptomatic (data not
shown). Patient 6 presented in infancy with CSA requir-
ing transfusions every three weeks. She has mild lactic
acidosis, no myopathy and intermittent neutropenia. She
has a c.590_645del variant resulting in a 12 amino acid
deletion in the catalytic domain (Figure 1A), which
would almost certainly lead to a completely dysfunction-
al protein, in trans with p.(Gly191Val). Individuals 8a and
8b also carry p.(Gly191Val) in trans with a predicted null
or severe loss-of-function allele, c.1360_1360insG,
p.(Ile454Serfs*10). This variant truncates the S4-like
domain which is thought to stabilize the interaction
with tRNATyr, and the deletion of the YARS2 S4-like
domain leads to a 100-fold reduced amino-acylation
activity in vitro.20 Patient 8a had sideroblastic anemia and
edema. Lactate was elevated only on exertion and the
patient did not have myopathy. Her sister (P8b) is
asymptomatic. Patient 8a also had a somatic mutation in
SF3B1 p.(Lys700Glu) that is strongly associated with
myelodysplastic syndromes with ringed sideroblasts.26
Based on the childhood presentation of her anemia and
exercise intolerance that was exacerbated significantly
decades later, and the fact that a mutation in SF3B1
would be exceptional in a patient under 30 years of age,
we infer the YARS2mutations to be the primary cause of
her anemia with the SF3B1 mutation occurring as a sec-
ondary somatic event, which exacerbated her anemia,
bringing her to clinical attention. In addition to the
reduced activity in vitro,5 support of the notion that
YARS2 p.(Gly191Val) contributes to the disease pheno-
type in these patients comes from the observation that
this variant is a disease modifier in Leber Hereditary
Optic Neuropathy (LHON); the three common LHON
mitochondrial DNA mutations have incomplete pene-
trance. However, all patients who carry both the LHON
m.11778G>A mtDNA disease-associated variant in com-
bination with a homozygous YARS2 p.(Gly191Val) geno-
type were symptomatic.11  
Patients 9a and 9b carried the YARS2 c.98C>A,
p.(Ser33*) nonsense variant, which would result in a null
allele, and the p.(Tyr236Cys) variant (Figure 1A and B) that
did not alter amino-acylation activity in vitro. In addition,
in silico analysis using Alamut did not predict that this vari-
ant would lead to alteration of an exonic splicing enhancer
site. Patient 9a presented in infancy with sideroblastic ane-
mia that has come and gone throughout his life. He has no
lactic acidosis or myopathy. He and his unaffected brother
have some dysmorphic features, which have not previ-
ously been reported in association with YARS2 variants,
but are typical of MLASA1 patients with pseudouridine
synthase 1 (PUS1) mutations.17,27 His genotypically concor-
dant fraternal twin (P9b) has only mild anemia and similar
facial dysmorphology, once again highlighting the poten-
tial for decreased penetrance and/or expressivity of the
disorder.
Interestingly, some YARS2 patients with myopathy, but
no sideroblastic anemia, have recently been reported by
Sommerville et al.9 They report  siblings with a homozy-
gous YARS2 p.(Leu392Ser) variant who had MLASA2,
while another individual homozygous for the same vari-
ant had myopathy without sideroblastic anemia or lactic
acidosis. 
To summarize, the inter- and intra-familial phenotypic
variability, intermittent transfusion dependence of some
YARS2 cases, and the association of a common variant
with disease, suggest that all MLASA2 phenotypes may
be susceptible to subtle changes in YARS2 function, which
may in turn be influenced by genetic and/or environmen-
tal modifiers. This study shows that YARS2 variants can
result in CSA in the absence of clinically significant
myopathy or lactic acidosis. Thus, we recommend that
YARS2 variants be considered as a cause of isolated sider-
oblastic anemia as well as MLASA2 or mitochondrial
myopathy.
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